^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MCM2 (Minichromosome maintenance complex component 2)

    i
    Other names: MCM2, BM28, CCNL1, cdc19, CDCL1, D3S3194, KIAA0030, Minichromosome maintenance complex component 2
    Associations

    News

    Trials
    14d
    Prognostic significance of ACADL and MCM2 in meningiomas: Current evidence and clinical implications. (PubMed, Histol Histopathol)
    Both markers correlated with higher WHO grades but lacked standardized assessment criteria, limiting their clinical application. While ACADL and MCM2 immunoexpression does not reliably substitute molecular classification, MCM2, in particular, holds potential for routine prognostic use pending further validation and standardization of immunohistochemical protocols.
    Review • Journal
    |
    MCM2 (Minichromosome maintenance complex component 2)
    20d
    CCNL1 Activates the NF-κB Pathway Through DVL3 Inhibition and PI3K/AKT Pathway Promotion in Breast Cancer. (PubMed, Mol Carcinog)
    CCNL1 overexpression affects breast cancer cells' paclitaxel sensitivity through the PI3K/AKT pathway. CCNL1 activates the NF-κB signaling pathway through its interaction with DVL3; additionally, it promotes the PI3K/AKT pathway. Together, these two mechanisms enable CCNL1 to exert a regulatory role in the progression of breast cancer.
    Journal
    |
    CDH1 (Cadherin 1) • VIM (Vimentin) • CCNL1 (Cyclin L1) • MCM2 (Minichromosome maintenance complex component 2)
    |
    paclitaxel
    28d
    Exploratory research on therapeutic agents combined with early diagnostic biomarkers for colorectal cancer. (PubMed, Front Pharmacol)
    This study systematically delineates a novel panel of early-detection biomarkers for CRC and identifies SB-225002 as a repurposed candidate therapeutic agent. The integrative strategy combining multi-cohort transcriptomic analysis, drug-repositioning platforms, molecular docking, and experimental validation offers a feasible framework for discovering clinically actionable biomarkers and small-molecule therapies for CRC.
    Journal
    |
    ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CXCL3 (C-X-C Motif Chemokine Ligand 3) • FABP4 (Fatty Acid Binding Protein 4) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MCM2 (Minichromosome maintenance complex component 2)
    |
    SB225002
    1m
    CDK1 depletion suppresses glioma malignancy through cell cycle pathway regulation: Mechanistic insights from functional and molecular profiling. (PubMed, Oncol Rep)
    The robust association between CDK1 expression, tumor grade and survival, coupled with functional validation across complementary assays, positions CDK1 inhibition as a promising therapeutic strategy. The mechanistic elucidation of its cell cycle network provides a novel framework for targeting glioma‑specific therapeutic targets..
    Journal
    |
    PLK1 (Polo Like Kinase 1) • PCNA (Proliferating cell nuclear antigen) • CDK1 (Cyclin-dependent kinase 1) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MCM2 (Minichromosome maintenance complex component 2) • MCM6 (Minichromosome Maintenance Complex Component 6)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    3ms
    Lidocaine suppresses HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis. (PubMed, Discov Oncol)
    In conclusion, this study reveals a novel mechanism by which lidocaine inhibits HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis, highlighting a potential therapeutic avenue for HER2-positive breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) • CCNL1 (Cyclin L1) • MCM2 (Minichromosome maintenance complex component 2)
    |
    HER-2 positive
    3ms
    CancerTrace: Multi-stage single-cell analysis of networked cancer evolution for driver and modulator gene identification. (PubMed, Comput Struct Biotechnol J)
    Driver coefficients for TP53INP1, CA12, and CCNL1 aligned with known biology, and epithelial drivers exerted measurable influence on NK cells, consistent with their stage-wise decline. By leveraging temporal single-cell structure, CancerTrace transcends the static and cohort-dependent limitations of existing tools, inferring causal, time-directed driver-modulator relationships that advance mechanistic understanding and precision oncology.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • CCNL1 (Cyclin L1) • MCM2 (Minichromosome maintenance complex component 2) • TP53INP1 (Tumor Protein P53 Inducible Nuclear Protein 1)
    3ms
    Protein kinase D2-mediated maintenance complex component 2 phosphorylation promotes bladder cancer progression. (PubMed, J Transl Med)
    These findings offer new insights into regulatory mechanisms involving PRKD2 contributing to the malignancy of bladder cancer, thereby presenting a potential therapeutic target.
    Journal
    |
    MCM2 (Minichromosome maintenance complex component 2)
    3ms
    TREM2 Alleviates Neuroinflammation and Improves Neurogenesis in ApoE-/- Mice by Regulating M1/M2 Microglial Polarization. (PubMed, Mol Neurobiol)
    Moreover, the mechanistic study indicated that overexpression of TREM2 modulated microglial M2 polarization and promoted the proliferation and differentiation of NSCs partly via the PI3K/Akt and ERK1/2 signaling pathways. Collectively, these findings revealed that TREM2 may modulate microglial M2 polarization to inhibit neuroinflammation and increase the M2 microglia-derived BDNF to rescue hippocampal neurogenesis in ApoE-/- mice, and TREM2 can be considered a promising therapeutic factor to promote neurogenesis in AD and other brain diseases.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • APOE (Apolipoprotein E) • ARG1 (Arginase 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • MCM2 (Minichromosome maintenance complex component 2) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    3ms
    High ORC6 expression is a prognostic indicator of poor survival in glioma patients. (PubMed, Sci Rep)
    ORC6 represents a highly promising novel target for precision therapy in glioma. Potential approaches to target this pathway include disrupting the ORC6-replication axis using existing drugs (such as palbociclib) or natural products (such as baicalin).
    Journal
    |
    CDC45 (Cell Division Cycle 45) • MCM2 (Minichromosome maintenance complex component 2) • ORC1 (Origin Recognition Complex Subunit 1) • MCM6 (Minichromosome Maintenance Complex Component 6)
    |
    Ibrance (palbociclib)
    4ms
    PCNA and MCM 2 in Odontogenic Tumors: An Immunnohistological Study. (PubMed, J Pharm Bioallied Sci)
    A strong correlation was also noted between increased MCM2 expression and local invasiveness of tumour (P < 0.05). We have studied the expression of MCM2 in a series of ameloblastomas (using an immunohistochemical method) and found this marker to be expressed at high levels; thus, it could potentially serve as a prognostic marker for these aggressive tumors.
    Journal
    |
    PCNA (Proliferating cell nuclear antigen) • MCM2 (Minichromosome maintenance complex component 2)
    4ms
    Decoding Cervical Cancer Biomarkers: An Integrated Framework of Bioinformatics, Machine Learning, and Experimental Confirmation. (PubMed, Cancer Invest)
    The ML models were developed using significantly differentially expressed genes (DEGs) involved in important pathways for cervical cancer. ML prediction models are available at https://github.com/PGlab-NIPER/CC_Pred.
    Journal
    |
    PLK1 (Polo Like Kinase 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • MCM2 (Minichromosome maintenance complex component 2)